BECCIOLINI, ANDREA
BECCIOLINI, ANDREA
Universita' degli Studi di MILANO
Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects
2019 C. Crotti, E. Agape, A. Becciolini, M. Biggioggero, E.G. Favalli
Tocilizumab in the treatment of rheumatoid arthritis : An evidence-based review and patient selection
2019 M. Biggioggero, C. Crotti, A. Becciolini, E.G. Favalli
Sex and Management of Rheumatoid Arthritis
2019 E.G. Favalli, M. Biggioggero, C. Crotti, A. Becciolini, M.G. Raimondo, P.L. Meroni
Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis
2019 C. Crotti, M. Biggioggero, A. Becciolini, E. Agape, E.G. Favalli
Vitamin D and spondyloarthritis: Review of the literature
2018 C. Crotti, A. Becciolini, M. Biggioggero, E.G. Favalli
Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors : real-life data from the LORHEN registry
2018 E.G. Favalli, L. Sinigaglia, A. Becciolini, V. Grosso, R. Gorla, C. Bazzani, F. Atzeni, P. Sarzi-Puttini, E. Fusaro, R. Pellerito, R. Caporali
The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept : Retrospective analysis of a local registry
2018 E.G. Favalli, A. Becciolini, M. Biggioggero, I. Bertoldi, C. Crotti, M.G. Raimondo, A. Marchesoni
Sarilumab : patient-reported outcomes in rheumatoid arthritis
2018 C. Crotti, M. Biggioggero, A. Becciolini, E.G. Favalli
The profiling of axial spondyloarthritis patient candidate to a biologic therapy : consensus from a Delphi-panel of Italian experts
2018 E.G. Favalli, A. Becciolini, R. Caporali, M. Todoerti, F. Iannone, L. Dinoia, M. Sebastiani, A. Spinella, E. Gremese, F. Cianci, F. Atzeni, F. Bandinelli, G. Ferraccioli, G. Lapadula
The Expanded Risk Score in Rheumatoid Arthritis (ERS-RA): performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthrit
2018 F. Salaffi, M. Carotti, M. Di Carlo, M. Tardella, V. Lato, A. Becciolini, E.G. Favalli, A. Giovagnoni
Spotlight on mavrilimumab for the treatment of rheumatoid arthritis : Evidence to date
2017 C. Crotti, M.G. Raimondo, A. Becciolini, M. Biggioggero, E.G. Favalli
A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: Focus on interchangeability
2017 A. Becciolini, M.G. Raimondo, C. Crotti, E. Agape, M. Biggioggero, E.G. Favalli
The 12-item psoriatic arthritis impact of disease questionnaire : Construct validity, reliability, and interpretability in a clinical setting
2017 M. Di Carlo, A. Becciolini, V. Lato, C. Crotti, E.G. Favalli, F. Salaffi
Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations : similarities and differences
2017 E.G. Favalli, I. Pontikaki, A. Becciolini, M. Biggioggero, N. Ughi, M. Romano, C. Crotti, M. Gattinara, V. Gerloni, A. Marchesoni, P.L. Meroni
Change over time in the pattern of clinical response to first-line biologic drugs in patients with rheumatoid arthritis: Observational data in a real-life setting
2017 E.G. Favalli, A. Becciolini, P.L. Meroni
The management of first-line biologic therapy failures in rheumatoid arthritis : current practice and future perspectives
2017 E.G. Favalli, M.G. Raimondo, A. Becciolini, C. Crotti, M. Biggioggero, R. Caporali
Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis
2016 F. Cantini, L. Niccoli, C. Nannini, E. Cassara, O. Kaloudi, E.G. Favalli, A. Becciolini, M. Biggioggero, M. Benucci, F. Li Gobbi, V. Grossi, M. Infantino, F. Meacci, M. Manfredi, S. Guiducci, S. Bellando-Randone, M. Matucci-Cerinic, R. Foti, M. Di Gangi, M. Mosca, C. Tani, F. Palmieri, D. Goletti
Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis : A multi-center retrospective analysis
2016 E.G. Favalli, C. Selmi, A. Becciolini, M. Biggioggero, A. Ariani, D. Santilli, E. Fusaro, S. Parisi, M. Massarotti, A. Marchesoni, P.L. Meroni
The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry
2016 A. Becciolini, M. Biggioggero, E.G. Favalli
Is there a need for new thresholds to define remission and low disease activity by disease activity score 28 calculated with C reactive protein? real life data from a local registry
2015 E.G. Favalli, A. Becciolini, M. Biggioggero, A. Marchesoni, P.L. Meroni